Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
PHASE1
The purpose of this study is to test any good or bad effects of the study d...
Status
Completed
Location
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
PHASE1
This is a multi-center, open-label study to evaluate the safety, pharmacoki...
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
PHASE1
This study is designed to determine the recommended phase 2 dose (RP2D), an...